These cases are being handled separately because the medical science involved is distinct from the gastrointestinal claims, and because the defendants include both Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound)
Inconsistent timing: While semaglutide offers flexibility in administration time, maintaining consistency helps establish a routine and reduces the likelihood of missed doses
Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, et al
Increasing the dose while side effects are active will amplify those effects, not resolve them
Kohjima M, Enjoji M, Higuchi N et al (2007) Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease
Would be curious to see a similar long term persistence study specifically in diabetes